Industry News/Therapy

Betafectin PGG-Glucan Hematopoietic Activity Reported

Published in Blood Weekly, September 11th, 1995

Researchers from the New England Deaconess Hospital, Harvard Medical School and Alpha-Beta Technology, Inc., Worcester, Massachusetts, presented preclinical data that indicates Betafectin PGG-Glucan may enhance bone marrow recovery following chemotherapy.

The data were reported at the annual meeting of the International Society of Experimental Hematology in Dusseldorf, Germany.

"The results of these and earlier studies provide support for the use of Betafectin to restore white blood cell and platelet populations following cancer chemotherapy. These studies and additional data generated by our collaborators, are the foundation of the clinical program...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry